Y
Yi Lin
Researcher at Mayo Clinic
Publications - 367
Citations - 16846
Yi Lin is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 43, co-authored 273 publications receiving 10401 citations.
Papers
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu,Sudhakar Tummala,Partow Kebriaei,William G. Wierda,Cristina Gutierrez,Frederick L. Locke,Krishna V. Komanduri,Yi Lin,Nitin Jain,Naval Daver,Jason R. Westin,Alison M. Gulbis,Monica Loghin,John de Groot,Sherry Adkins,Suzanne E. Davis,Katayoun Rezvani,Patrick Hwu,Elizabeth J. Shpall +18 more
TL;DR: The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided.
Journal ArticleDOI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke,Armin Ghobadi,Caron A. Jacobson,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Jeffrey S. Wiezorek,Lynn Navale,Allen Xue,Yizhou Jiang,Adrian Bot,John M. Rossi,Jenny J. Kim,William Y. Go,Sattva S. Neelapu +30 more
TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.
Journal ArticleDOI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje,Jesus G. Berdeja,Yi Lin,David S. Siegel,Sundar Jagannath,Deepu Madduri,Michaela Liedtke,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Richard A. Morgan,Kevin G. Friedman,Monica Massaro,Julie Wang,Greg Russotti,Zhihong Yang,Timothy B. Campbell,Kristen Hege,Fabio Petrocca,M. Travis Quigley,Nikhil C. Munshi,James N. Kochenderfer +22 more
TL;DR: The initial toxicity profile of a BCMA‐directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma is reported andCAR T‐cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion.
Journal ArticleDOI
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja,Deepu Madduri,Saad Z. Usmani,Andrzej Jakubowiak,Mounzer Agha,Adam D. Cohen,A. Keith Stewart,Parameswaran Hari,Myo Htut,Alexander M. Lesokhin,Abhinav Deol,Nikhil C. Munshi,Elizabeth O'Donnell,David Avigan,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Yunsi Olyslager,Arnob Banerjee,Carolyn C. Jackson,Jenna D. Goldberg,Jordan M. Schecter,William Deraedt,Sen Hong Zhuang,Jeffrey R. Infante,Dong Geng,Xiaoling Wu,Marlene J Carrasco-Alfonso,Muhammad Akram,Farah Hossain,Syed Rizvi,Frank Fan,Yi Lin,Thomas Martin,Sundar Jagannath +35 more
TL;DR: The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.